Published Date: 07-02-2018
Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
According to a new report LAMEA Contrast Injector Systems Market, published by KBV research, the LAMEA Contrast Injector Systems Market would witness market growth of 9.5% CAGR during the forecast period (2018 – 2024).
The Brazil market dominated the LAMEA Injector Systems Market by Country in 2017. The Argentina market is expected to witness a CAGR of 10.8% during (2018 - 2024). Additionally, The UAE market is expected to witness a CAGR of 7.8% during (2018 - 2024).
The Radiology market would dominate the LAMEA Contrast Injector Systems Market by 2024. The Interventional Radiology market is expected to witness a CAGR of 9.2% during (2018 - 2024).
The Hospitals market dominated the UAE Contrast Injector Systems Market and would achieve a market value of $6.9 million by 2024. The Diagnostics Centers market is expected to witness a CAGR of 6.8% during (2018 - 2024).
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the mentioned countries. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Bayer Ag, Angiodynamics Inc., GE Healthcare (A Healthcare Division of GE Company), Medtron AG, Nemoto Kyorindo Co., Ltd., Sino Medical- Device Technology Co., Ltd., Shenzhen Seacrown Electromechanical Co., Ltd., Ulrich GmbH & Co. Kg, Vivid Imaging and Guerbet Group.
By End User
Unique Offerings from KBV Research